UP NEXT...
November 21, 2025 Seminar
-
Mead Lockwood
Collins LabUlcerative colitis is a chronic autoimmune disease of the colonic epithelium that substantially impacts patient quality of life. Biologic therapies have revolutionized the treatment of ulcerative colitis, however their systemic delivery can lead to serious adverse effects that constrain their overall utility. Here, we detail our work to engineer the probiotic yeast Saccharomyces boulardii as an enterically targeted living therapeutic for ulcerative colitis that enables localized delivery of biologic therapies to active sites of disease.
-
Nickeisha Cuthbert
Niles LabPlasmodium falciparum is the deadliest cause of human malaria. Although front-line antimalarials like
artemisinin (ART) have significantly reduced the malaria burden, cases of P. falciparum parasites that survive ART exposure are increasing. Dysregulation of the Pfkelch13 gene is implicated in ART resistance, though its precise function within the parasite remains unclear. We utilized a conditional knockdown (cKD) system in an assay designed to modulate Pfkelch13 expression and assess the effect on P. falciparum survival and resistance to ART.
All Seminars
Filter by
December 4, 2025 Seminar
-
Robbie Majzner
Drawing on Biologic Principles to Engineer More Effective Cancer Immunotherapies
December 5, 2025 Seminar
-
Patrick Song
Belcher Lab -
Rachel Myers
Belcher Lab Hammond Lab
February 5, 2026 Seminar
-
Douglas A. Lauffenburger
March 5, 2026 Seminar
-
Melanie Graham
March 12, 2026 Seminar
-
Dan Dongeun Huh
March 19, 2026 Seminar
-
Jennifer L. Wilson